


FORM-PTO-1449/A and B (modified PTO/SB/08)		APPLICATION NO.: 10/735,592	ATTY. DOCKET NO.: C1037.70038US01
INFORMATION DISCLOSURE STATEMENT BY APPLICANT 		FILING DATE: December 11, 2003	CONFIRMATION NO.: 2533
		APPLICANT: Krieg et al.	
		GROUP ART UNIT: 1645	EXAMINER: Nita M. Minnifield
Sheet	1	of	14

U.S. PATENT DOCUMENTS

Examiner's Initials [#]	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication or Issue of Cited Document MM-DD-YYYY
		Number	Kind Code		
NMM	A103	3,906,092		Hilleman et al.	09-16-1975
	A104	5,087,617		Smith	02-11-1992
	A105	5,457,189		Crooke et al.	10-10-1995
	A106	5,475,096		Gold et al.	12-12-1995
	A107	5,514,577		Draper et al.	05-07-1996
	A108	5,576,208		Monia et al.	11-19-1996
	A109	5,576,302		Cook et al.	11-19-1996
	A110	5,582,986		Monia et al.	12-10-1996
	A111	5,663,153		Hutcherson et al.	09-02-1997
	A112	5,684,147		Agrawal et al.	11-04-1997
	A113	5,696,249		Gold et al.	12-09-1997
	A114	5,726,160		McMichael	03-10-1998
	A115	5,843,653		Gold et al.	12-01-1998
	A116	5,955,059		Gilchrest et al.	09-21-1999
	A117	5,968,909		Agrawal et al.	10-19-1999
	A118	5,977,340		Pirotzky et al.	11-02-1999
	A119	5,994,315		Nyce et al.	11-30-1999
	A120	6,025,339		Nyce et al.	02-15-2000
	A121	6,031,086		Switzer	02-29-2000
	A122	6,040,296		Nyce et al.	03-21-2000
	A123	6,090,791		Sato et al.	07-18-2000
	A124	6,121,434		Peyman et al.	09-19-2000
	A125	6,184,369	B1	Rando et al.	02-06-2001
	A126	6,221,882		Macfarlane	04-24-2001
	A127	6,225,292	B1	Raz et al.	05-01-2001
	A128	6,339,630		Macfarlane	06-04-2002
	A129	6,348,312		Peyman et al.	02-19-2002
	A130	6,426,334	B1	Agrawal et al.	07-30-2002
	A131	6,476,000	B1	Agrawal et al.	11-05-2002
	A132	6,479,504		Macfarlane et al.	11-12-2002
	A133	6,498,147	B1	Nerenberg et al.	12-24-2002
NMM	A134	6,503,533	B1	Korba et al.	01-07-2003

EXAMINER: /N. M. Minnifield/ (10/20/2006)	DATE CONSIDERED: 10/20/2006
--	------------------------------------

[#] EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449/A and B (modified PTO/SB/08) INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICATION NO.: 10/735,592		ATTY. DOCKET NO.: C1037.70038US01			
				FILING DATE: December 11, 2003		CONFIRMATION NO.: 2533			
				APPLICANT: Krieg et al.					
				GROUP ART UNIT: 1645		EXAMINER: Nita M. Minnifield			
Sheet	2	of	14						

NMM	A135	6,521,637		Macfarlane	02-18-2003
	A136	6,558,670	B1	Friede et al.	05-06-2003
	A137	6,605,708		Habus et al.	08-12-2003
	A138	6,613,751	B1	Raz et al.	09-02-2003
	A139	6,693,086	B1	Dow et al.	02-17-2004
	A140	6,737,066	B1	Moss	05-18-2004
	A141	6,821,957	B1	Krieg et al.	11-23-2004
	A142	6,835,395	B1	Semple et al.	12-28-2004
	A143	6,943,240		Bauer et al.	09-13-2005
	A144	6,949,520		Hartmann et al.	09-27-2005
	A145	7,001,890		Wagner et al.	02-26-2006
	A146	2001-0021772	A1	Uhlmann et al.	09-13-2001
	A147	2001-0046967	A1	Van Nest et al.	11-29-2001
	A148	2002-0028784	A1	Van Nest et al.	03-07-2002
	A149	2002-0042387	A1	Raz et al.	04-11-2002
	A150	2002-0055477	A1	Van Nest et al.	05-09-2002
	A151	2002-0086839	A1	Raz et al.	07-04-2002
	A152	2002-0098199	A1	Van Nest et al.	07-25-2002
	A153	2002-0102255	A1	Chang	08-01-2002
	A154	2002-0107212	A1	Van Nest et al.	08-08-2002
	A155	2002-0137714	A1	Kandamilla et al.	09-26-2002
	A156	2002-0142977	A1	Raz et al.	10-03-2002
	A157	2002-0142978	A1	Raz et al.	10-03-2002
	A158	2002-0192184	A1	Carpentier et al.	12-19-2002
	A159	2003-0022852	A1	Van Nest et al.	01-30-2003
	A160	2003-0049266	A1	Fearon et al.	03-13-2003
	A161	2003-0059773	A1	Van Nest et al.	03-27-2003
	A162	2003-0060440	A1	Klinman et al.	03-27-2003
	A163	2003-0064064	A1	Dina et al.	04-03-2003
	A164	2003-0078223	A1	Raz et al.	04-24-2003
	A165	2003-0092663	A1	Raz et al.	05-15-2003
	A166	2003-0104044	A1	Semple et al.	06-05-2003
	A167	2003-0119773	A1	Raz et al.	06-26-2003
	A168	2003-0125284	A1	Raz et al.	07-03-2003
V	A169	2003-0129251	A1	Van Nest et al.	07-10-2003
NMM	A170	2003-0130217	A1	Raz et al.	07-10-2003

EXAMINER: /N. M. Minnifield/ (10/20/2006)	DATE CONSIDERED: 10/20/2006
--	--------------------------------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449/A and B (modified PTO/SB/08) INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICATION NO.: 10/735,592		ATTY. DOCKET NO.: C1037.70038US01	
				FILING DATE: December 11, 2003		CONFIRMATION NO.: 2533	
				APPLICANT: Krieg et al.			
				GROUP ART UNIT: 1645		EXAMINER: Nita M. Minnifield	
Sheet	3	of	14				

NMM	A171	2003-0133988	A1	Fearon et al.	07-17-2003
	A172	2003-0143213	A1	Raz et al.	07-31-2003
	A173	2003-0147870	A1	Raz et al.	08-07-2003
	A174	2003-0165478	A1	Sokoll et al.	09-04-2003
	A175	2003-0175731	A1	Fearon et al.	09-18-2003
	A176	2003-0176373	A1	Raz et al.	09-18-2003
	A177	2003-0176389	A1	Raz et al.	09-18-2003
	A178	2003-0199466	A1	Fearon et al.	10-23-2003
	A179	2003-0212026	A1	Krieg et al.	11-13-2003
	A180	2003-0212028	A1	Raz et al.	11-13-2003
	A181	2003-0216340	A1	Van Nest et al.	11-20-2003
	A182	2003-0224010	A1	Davis et al.	12-04-2003
	A183	2003-0225016	A1	Fearon et al.	12-04-2003
	A184	2003-0232780	A1	Carson et al.	12-18-2003
	A185	2003-0232856	A1	Macfarlane	12-18-2003
	A186	2004-0006010	A1	Carson et al.	01-08-2004
	A187	2004-0006034	A1	Raz et al.	01-08-2004
	A188	2004-0009942	A1	Van Nest et al.	01-15-2004
	A189	2004-0013688	A1	Wise et al.	01-22-2004
	A190	2004-0030118	A1	Wagner et al.	02-12-2004
	A191	2004-0038922	A1	Haensler et al.	02-26-2004
	A192	2004-0053880	A1	Krieg	03-18-2004
	A193	2004-0058883	A1	Phillips et al.	03-25-2004
	A194	2004-0067902	A9	Bratzler et al.	04-08-2004
	A195	2004-0067905	A1	Krieg	04-08-2004
	A196	2004-0087534	A1	Krieg et al.	05-06-2004
	A197	2004-0087538	A1	Krieg et al.	05-06-2004
	A198	2004-0092468	A1	Schwartz et al.	05-13-2004
	A199	2004-0092472	A1	Krieg	05-13-2004
	A200	2004-0097719	A1	Agrawal et al.	05-20-2004
	A201	2004-0105872	A1	Klinman et al.	06-03-2004
	A202	2004-0106568	A1	Krieg et al.	06-03-2004
	A203	2004-0115219	A1	Ahn et al.	06-17-2004
	A204	2004-0131628	A1	Bratzler et al.	07-08-2004
	A205	2004-0132677	A1	Fearon et al.	07-08-2004
NMM	A206	2004-0132685	A1	Krieg et al.	07-08-2004

EXAMINER: /N. M. Minnifield/ (10/20/2006)	DATE CONSIDERED: 10/20/2006
---	-----------------------------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449/A and B (modified PTO/SB/08) INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICATION NO.: 10/735,592		ATTY. DOCKET NO.: C1037.70038US01	
				FILING DATE: December 11, 2003		CONFIRMATION NO.: 2533	
				APPLICANT: Krieg et al.			
				GROUP ART UNIT: 1645		EXAMINER: Nita M. Minnifield	
Sheet	4	of	14				

NMM	A207	2004-0136948	A1	Fearon et al.	07-15-2004
	A208	2004-0142469	A1	Krieg et al.	07-22-2004
	A209	2004-0143112	A1	Krieg et al.	07-22-2004
	A210	2004-0147468	A1	Krieg et al.	07-29-2004
	A211	2004-0152649	A1	Krieg	08-05-2004
	A212	2004-0152656	A1	Krieg et al.	08-05-2004
	A213	2004-0152657	A1	Krieg et al.	08-05-2004
	A214	2004-0162258	A1	Krieg et al.	08-19-2004
	A215	2004-0162262	A1	Krieg et al.	08-19-2004
	A216	2004-0167089	A1	Krieg et al.	08-26-2004
	A217	2004-0171150	A1	Krieg et al.	09-02-2004
	A218	2004-0171571	A1	Krieg et al.	09-02-2004
	A219	2004-0181045	A1	Krieg et al.	09-16-2004
	A220	2004-0198680	A1	Krieg	10-07-2004
	A221	2004-0198688	A1	Krieg et al.	10-07-2004
	A222	2004-0229835	A1	Krieg et al.	11-18-2004
	A223	2004-0234512	A1	Wagner et al.	11-25-2004
	A224	2004-0235770	A1	Davis et al.	11-25-2004
	A225	2004-0235774	A1	Bratzler et al.	11-25-2004
	A226	2004-0235777	A1	Wagner et al.	11-25-2004
	A227	2004-0235778	A1	Wagner et al.	11-25-2004
	A228	2004-0247662	A1	Dow et al.	12-09-2004
	A229	2004-0248837	A1	Raz et al.	12-09-2004
	A230	2004-0266719	A1	McCluskie et al.	12-30-2004
	A231	2005-0004061	A1	Krieg et al.	01-06-2005
	A232	2005-0004062	A1	Krieg et al.	01-06-2005
	A233	2005-0004144	A1	Carson et al.	01-06-2005
	A234	2005-0009774	A1	Krieg et al.	01-13-2005
	A235	2005-0013812	A1	Dow et al.	01-20-2005
	A236	2005-0031638	A1	Dalemans et al.	02-10-2005
	A237	2005-0032734	A1	Davis et al.	02-10-2005
	A238	2005-0032736	A1	Krieg et al.	02-10-2005
	A239	2005-0037403	A1	Krieg et al.	02-17-2005
	A240	2005-0037985	A1	Krieg et al.	02-17-2005
NMM	A241	2005-0043529	A1	Davis et al.	02-24-2005
	A242	2005-0049215	A1	Krieg et al.	03-03-2005

EXAMINER: NMM NMM NMM	/N. M. Minnifield/ (10/20/2006)	DATE CONSIDERED: 10/20/2006
------------------------------------	---------------------------------	------------------------------------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449/A and B (modified PTO/SB/08) INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICATION NO.: 10/735,592		ATTY. DOCKET NO.: C1037.70038US01	
				FILING DATE: December 11, 2003		CONFIRMATION NO.: 2533	
				APPLICANT: Krieg et al.			
				GROUP ART UNIT: 1645		EXAMINER: Nita M. Minnifield	
Sheet	5	of	14				

NMM	A243	2005-0049216	A1	Krieg et al.	03-03-2005
	A244	2005-0054601	A1	Wagner et al.	03-10-2005
	A245	2005-0054602	A1	Krieg et al.	03-10-2005
	A246	2005-0059619	A1	Krieg et al.	03-17-2005
	A247	2005-0059625	A1	Krieg et al.	03-17-2005
	A248	2005-0059626	A1	Van Nest et al.	03-17-2005
	A249	2005-0064401	A1	Olek et al.	03-24-2005
	A250	2005-0070491	A1	Krieg et al.	03-31-2005
	A251	2005-0075302	A1	Hutcherson et al.	04-07-2005
	A252	2005-0100983	A1	Bauer et al.	05-12-2005
	A253	2005-0101554	A1	Krieg et al.	05-12-2005
	A254	2005-0101557	A1	Krieg et al.	05-12-2005
	A255	2005-0119273	A1	Lipford et al.	06-02-2005
	A256	2005-0123523	A1	Krieg et al.	06-09-2005
	A257	2005-0130911	A1	Uhlmann et al.	06-16-2005
	A258	2005-0130918	A1	Agrawal et al.	06-16-2005
	A259	2005-0148537	A1	Krieg et al.	07-07-2005
	A260	2005-0152921	A1	Kim et al.	07-14-2005
	A261	2005-0158336	A1	Diamond et al.	07-21-2005
	A262	2005-0159351	A1	Grate et al.	07-21-2005
	A263	2005-0159375	A1	Srivastava et al.	07-21-2005
	A264	2005-0169888	A1	Hartman et al.	08-04-2005
	A265	2005-0171047	A1	Krieg et al.	08-04-2005
	A266	2005-0176672	A1	Scheule et al.	08-11-2005
	A267	2005-0181422	A1	Bauer et al.	08-18-2005
	A268	2005-0182017	A1	Krieg	08-18-2005
	A269	2005-0191342	A1	Tam et al.	09-01-2005
	A270	2005-0196411	A1	Moss et al.	09-08-2005
	A271	2005-0197314	A1	Krieg et al.	09-08-2005
	A272	2005-0203039	A1	Jeon et al.	09-15-2005
	A273	2005-0209183	A1	Kippenberger et al.	09-22-2005
	A274	2005-0209184	A1	Klinman et al.	09-22-2005
	A275	2005-0214355		Klinman et al.	09-29-2005
	A276	2005-0215500	A1	Krieg et al.	09-29-2005
V	A277	2005-0215501	A1	Lipford et al.	09-29-2005
NMM	A278	2005-0233995	A1	Krieg et al.	10-20-2005

EXAMINER:	/N. M. Minnifield/ (10/20/2006)	DATE CONSIDERED:	10/20/2006
-----------	---------------------------------	------------------	------------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449/A and B (modified PTO/SB/08) INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICATION NO.: 10/735,592		ATTY. DOCKET NO.: C1037.70038US01	
				FILING DATE: December 11, 2003		CONFIRMATION NO.: 2533	
				APPLICANT: Krieg et al.			
				GROUP ART UNIT: 1645		EXAMINER: Nita M. Minnifield	
Sheet	6	of	14				

NMM	A279	2005-0233999	A1	Krieg et al.	10-20-2005
	A280	2005-0239732	A1	Krieg et al.	10-27-2005
	A281	2005-0239733	A1	Jurk et al.	10-27-2005
	A282	2005-0239734	A1	Uhlmann et al.	10-27-2005
	A283	2005-0239736	A1	Krieg et al.	10-27-2005
	A284	2005-0245477	A1	Krieg et al.	11-03-2005
	A285	2005-0244379	A1	Krieg et al.	11-03-2005
	A286	2005-0244380	A1	Krieg et al.	11-03-2005
	A287	2005-0250726	A1	Krieg et al.	11-10-2005
	A288	2005-0256073	A1	Lipford et al.	11-17-2005
	A289	2005-0267057	A1	Krieg	12-01-2005
	A290	2005-0267064	A1	Krieg et al.	12-01-2005
	A291	2005-0277604	A1	Krieg et al.	12-15-2005
	A292	2005-0277609	A1	Krieg et al.	12-15-2005
	A293	2006-0003955	A1	Krieg et al.	01-05-2006
	A294	2006-0003962	A1	Ahluwalia et al.	01-05-2006
	A295	2006-0019916	A1	Krieg et al.	01-26-2006
	A296	2006-0019923	A1	Davis et al.	01-26-2006
	A297	2006-0058251	A1	Krieg et al.	03-16-2006
	A298	2006-0089326	A1	Krieg et al.	04-27-2006
	A299	2006-0094683	A1	Krieg et al.	05-04-2006
NMM	A300	2006-0140875	A1	Krieg et al.	06-29-2006

FOREIGN PATENT DOCUMENTS

Examiner's Initials #	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Translation (Y/N)
		Office/ Country	Number	Kind Code			
NMM	B48	WO	90/14822	A1	Northwestern University	12-13-1990	
	B49	WO	95/17507	A1	Biagnostik Gesellschaft Für Biomolekulare Diagnostik MBH [DE]	06-29-1995	
	B50	WO	96/02555	A1	University of Iowa Research Foundation	02-01-1996	
	B51	WO	96/02560	A1	University of North Carolina at Chapel Hill	02-01-1996	
	B52	WO	96/40162	A1	East Carolina University	12-19-1996	
	B53	WO	98/11211	A2	Hybridon et al.	03-19-1998	
	B54	WO	98/49288	A1	Hybridon Inc.	11-05-1998	
	B55	WO	98/52962	A1	Merck and Co., Inc.	11-26-1998	
NMM	B56	WO	99/33488	A2	SmithKline Beecham Biologicals S.A.	07-08-1999	

EXAMINER: /N. M. Minnifield/ (10/20/2006)	DATE CONSIDERED: 10/20/2006
--	--------------------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449/A and B (modified PTO/SB/08) INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICATION NO.: 10/735,592		ATTY. DOCKET NO.: C1037.70038US01	
				FILING DATE: December 11, 2003		CONFIRMATION NO.: 2533	
				APPLICANT: Krieg et al.			
				GROUP ART UNIT: 1645		EXAMINER: Nita M. Minnifield	
Sheet	7	of	14				

NMM	B57	WO	99/33868	A2	SmithKline Beecham Biologicals, S.A.	07-08-1999	
	B58	WO	99/56755	A1	University of Iowa Research Foundation	11-11-1999	
	B59	WO	00/06588	A1	University of Iowa Research Foundation	02-10-2000	
	B60	WO	00/15256	A2	Pasteur Merieux Serums Et Vaccins [FR]	03-23-2000	Abstract
	B61	WO	00/23105	A2	SmithKline Beecham Biologicals, S.A.	04-27-2000	
	B62	WO	00/41463	A2	SmithKline Beecham Biologicals, S.A.	07-20-2000	
	B63	WO	00/46365	A1	Virginia Commonwealth University	08-10-2000	
	B64	WO	00/54803	A2	Panacea Pharmaceuticals, LLC.	09-21-2000	
	B65	WO	00/56359	A2	SmithKline Beecham Biologicals, S.A.	09-28-2000	
	B66	WO	00/61151	A2	The Government of the United States of America	10-19-2000	
	B67	WO	00/67787	A2	The Immune Response Corporation	11-16-2000	
	B68	WO	00/75304	A1	Aventis Pasteur [FR]	12-14-2000	Abstract
	B69	WO	01/00231	A2	SmithKline Beecham Biologicals, S.A.	01-04-2001	
	B70	WO	01/00232	A2	SmithKline Beecham Biologicals, S.A.	01-04-2001	
	B71	WO	01/17550	A2	SmithKline Beecham Biologicals, S.A.	03-15-2001	
	B72	WO	01/17551	A2	SmithKline Beecham Biologicals, S.A.	03-15-2001	
	B73	WO	01/54719	A2	SmithKline Beecham Biologicals, S.A.	08-02-2001	
	B74	WO	01/62909	A1	Aventis Pasteur [FR]	08-30-2001	Abstract
	B75	WO	01/93902	A2	Biosynexus Incorporated	12-13-2001	
	B76	WO	02/09748	A1	Yale University	02-07-2002	
	B77	WO	02/28428	A2	Aventis Pasteur [FR]	04-11-2002	Abstract
	B78	WO	02/102307	A2	Ribapharm	12-27-2002	
	B79	WO	03/002065	A2	Chiron Corporation	01-09-2003	
	B80	WO	03/025119	A2	Medarex Inc.	03-27-2003	
	B81	WO	03/026688	A1	Pharmaderm Laboratories, Ltd.	04-03-2003	
	B82	WO	03/035836	A2	Hybridon, Inc.	05-01-2003	
	B83	WO	03/066649	A1	Biomira Inc.	08-14-2003	
	B84	WO	2004/026888	A2	Coley Pharmaceutical GmbH	04-01-2004	
	B85	WO	2004/007743	A2	Coley Pharmaceutical GmbH	01-22-2004	
	B86	WO	2004/094671	A2	Coley Pharmaceutical GmbH	11-04-2004	
	B87	WO	2005/001055	A2	Hybridon Inc.	01-06-2005	
	B88	WO	2005/004910	A2	Intercell Ag	01-20-2005	
NMM	B89	WO	2005/023289	A1	Intellectual Property Consulting Incorporated	03-17-2005	Abstract

EXAMINER: /N. M. Minnifield/ (10/20/2006)	DATE CONSIDERED: 10/20/2006
--	------------------------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449/A and B (modified PTO/SB/08) INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICATION NO.: 10/735,592		ATTY. DOCKET NO.: C1037.70038US01	
				FILING DATE: December 11, 2003		CONFIRMATION NO.: 2533	
				APPLICANT: Krieg et al.			
				GROUP ART UNIT: 1645		EXAMINER: Nita M. Minnifield	
Sheet	8	of	14				

OTHER ART — NON PATENT LITERATURE DOCUMENTS

Examiner's Initials #	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)
NMM	C195	[No Author Listed] Antiviral Agents Bulletin. 5(6), 1992.	
	C196	AGRAWAL et al., Pharmacokinetics of oligonucleotides. Ciba Found Symp. 1997;209:60-75; discussion 75-8.	
	C197	AGRAWAL et al., Absorption, tissue distribution and in vivo stability in rats of a hybrid antisense oligonucleotide following oral administration. Biochem Pharmacol. 1995 Aug 8;50(4):571-6.	
	C198	AGRAWAL et al., In vivo pharmacokinetics of phosphorothioate oligonucleotides containing contiguous guanosines. Antisense Nucleic Acid Drug Dev. 1997 Jun;7(3):245-9.	
	C199	AGRAWAL et al., Novel immunomodulatory oligonucleotides prevent development of allergic airway inflammation and airway hyperresponsiveness in asthma. Int Immunopharmacol. 2004 Jan;4(1):127-38.	
	C200	AGRAWAL et al., Antisense therapeutics: is it as simple as complementary base recognition? Mol Med Today. 2000 Feb;6(2):72-81.	
	C201	AGRAWAL et al., Pharmacokinetics, biodistribution, and stability of oligodeoxynucleotide phosphorothioates in mice. Proc Natl Acad Sci U S A. 1991 Sep 1;88(17):7595-9.	
	C202	AGRAWAL et al., Medicinal chemistry and therapeutic potential of CpG DNA. Trends Mol Med. 2002 Mar;8(3):114-21.	
	C203	AGRAWAL et al., Pharmacokinetics of antisense oligonucleotides. Clin Pharmacokinet. 1995 Jan;28(1):7-16.	
	C204	AMMERPOHL et al., Complex protein binding to the mouse M-lysozyme gene downstream enhancer involves single-stranded DNA binding. Gene. 1997 Oct 24;200(1-2):75-84.	
	C205	AN et al., Isoforms of the EP3 subtype of human prostaglandin E2 receptor transduce both intracellular calcium and cAMP signals. Biochemistry. 1994 Dec 6;33(48):14496-502.	
	C206	ANDERSON et al., Selective inhibition of cyclooxygenase (COX)-2 reverses inflammation and expression of COX-2 and interleukin 6 in rat adjuvant arthritis. J Clin Invest. 1996 Jun 1;97(11):2672-9.	
	C207	ANITESCU et al., Interleukin-10 functions in vitro and in vivo to inhibit bacterial DNA-induced secretion of interleukin-12. J Interferon Cytokine Res. 1997 Dec;17(12):781-8.	
	C208	BALLAS et al., Divergent therapeutic and immunologic effects of oligodeoxynucleotides with distinct CpG motifs. J Immunol. 2001 Nov 1;167(9):4878-86.	
	C209	BOCHNER et al., Advances in mechanisms of allergy. J Allergy Clin Immunol. 2004 May;113(5):868-75.	
	C210	BOHLE et al., Oligodeoxynucleotides containing CpG motifs induce IL-12, IL-18 and IFN-gamma production in cells from allergic individuals and inhibit IgE synthesis in vitro. Eur J Immunol. 1999 Jul;29(7):2344-53.	
	C211	BROIDE et al., Immunostimulatory DNA sequences inhibit IL-5, eosinophilic inflammation, and airway hyperresponsiveness in mice. J Immunol. 1998 Dec 15;161(12):7054-62.	
V	C212	BROIDE et al., Modulation of asthmatic response by immunostimulatory DNA sequences. Springer Semin Immunopathol. 2000;22(1-2):117-24.	
NMM	C213	BROIDE et al., DNA-Based immunization for asthma. Int Arch Allergy Immunol. 1999 Feb-Apr;118(2-4):453-6.	

EXAMINER: /N. M. Minnifield/ (10/20/2006)	DATE CONSIDERED: 10/20/2006
--	------------------------------------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449/A and B (modified PTO/SB/08) INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICATION NO.: 10/735,592		ATTY. DOCKET NO.: C1037.70038US01	
				FILING DATE: December 11, 2003		CONFIRMATION NO.: 2533	
				APPLICANT: Krieg et al.			
				GROUP ART UNIT: 1645		EXAMINER: Nita M. Minnifield	
Sheet	9	of	14				

NMM	C214	CARSON et al., Oligonucleotide adjuvants for T helper 1 (Th1)-specific vaccination. J Exp Med. 1997 Nov 17;186(10):1621-2.	
	C215	CHACE et al., Bacterial DNA-induced NK cell IFN-gamma production is dependent on macrophage secretion of IL-12. Clin Immunol Immunopathol. 1997 Aug;84(2):185-93.	
	C216	CHU et al., CpG oligodeoxynucleotides down-regulate macrophage class II MHC antigen processing. J Immunol. 1999 Aug 1;163(3):1188-94.	
	C217	CROOKE et al., Phosphorothioate Oligonucleotides. Therapeut Apps. 1995;ch5:63-84.	
	C218	CROOKE et al., Progress in antisense oligonucleotide therapeutics. Annu Rev Pharmacol Toxicol. 1996;36:107-29.	
	C219	DALPKE et al., Phosphodiester CpG oligonucleotides as adjuvants: polyguanosine runs enhance cellular uptake and improve immunostimulative activity of phosphodiester CpG oligonucleotides in vitro and in vivo. Immunology. 2002 May;106(1):102-12.	
	C220	FILION et al., Major limitations in the use of cationic liposomes for DNA delivery. Int J Pharmaceut. 1998; 162:159-70.	
	C221	GOMIS et al., Protection of chickens against Escherichia coli infections by DNA containing CpG motifs. Infect Immun. 2003 Feb;71(2):857-63.	
	C222	GROSSMANN et al., Avoiding tolerance against prostatic antigens with subdominant peptide epitopes. J Immunother. 2001 May-Jun;24(3):237-41.	
	C223	GURSEL et al., Sterically stabilized cationic liposomes improve the uptake and immunostimulatory activity of CpG oligonucleotides. J Immunol. 2001 Sep 15;167(6):3324-8.	
	C224	GURSEL et al., Differential and competitive activation of human immune cells by distinct classes of CpG oligodeoxynucleotide. J Leukoc Biol. 2002 May;71(5):813-20. Abstract Only.	
	C225	HARTMANN et al., CpG DNA and LPS induce distinct patterns of activation in human monocytes. Gene Ther. 1999 May;6(5):893-903.	
	C226	HARTMANN et al., Spontaneous and cationic lipid-mediated uptake of antisense oligonucleotides in human monocytes and lymphocytes. J Pharmacol Exp Ther. 1998 May;285(2):920-8.	
	C227	IOANNOU et al., The immunogenicity and protective efficacy of bovine herpesvirus 1 glycoprotein D plus Emulsigen are increased by formulation with CpG oligodeoxynucleotides. J Virol. 2002 Sep;76(18):9002-10.	
	C228	JAIN et al., CpG-oligodeoxynucleotides inhibit airway remodeling in a murine model of chronic asthma. J Allergy Clin Immunol. 2002 Dec;110(6):867-72.	
	C229	JAIN et al., CpG DNA and immunotherapy of allergic airway diseases. Clin Exp Allergy. 2003 Oct;33(10):1330-5.	
	C230	JAIN et al., CpG DNA: immunomodulation and remodelling of the asthmatic airway. Expert Opin Biol Ther. 2004 Sep;4(9):1533-40.	
	C231	KANDIMALLA et al., A dinucleotide motif in oligonucleotides shows potent immunomodulatory activity and overrides species-specific recognition observed with CpG motif. Proc Natl Acad Sci U S A. 2003 Nov 25;100(24):14303-8.	
	C232	KANDIMALLA et al., Towards optimal design of second-generation immunomodulatory oligonucleotides. Curr Opin Mol Ther. 2002 Apr;4(2):122-9.	
NMM	C233	KANDIMALLA et al., Divergent synthetic nucleotide motif recognition pattern: design and development of potent immunomodulatory oligodeoxyribonucleotide agents with distinct cytokine induction profiles. Nucleic Acids Res. 2003 May 1;31(9):2393-400.	

EXAMINER: /N. M. Minnifield/ (10/20/2006)	DATE CONSIDERED: 10/20/2006
--	--------------------------------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449/A and B (modified PTO/SB/08) INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICATION NO.: 10/735,592		ATTY. DOCKET NO.: C1037.70038US01	
				FILING DATE: December 11, 2003		CONFIRMATION NO.: 2533	
				APPLICANT: Krieg et al.			
				GROUP ART UNIT: 1645		EXAMINER: Nita M. Minnifield	
Sheet	10	of	14				

NMM	C234	KANDIMALLA et al., Effect of chemical modifications of cytosine and guanine in a CpG-motif of oligonucleotides: structure-immunostimulatory activity relationships. Bioorg Med Chem. 2001 Mar;9(3):807-13.	
	C235	KATAOKA et al., Immunotherapeutic potential in guinea-pig tumor model of deoxyribonucleic acid from Mycobacterium bovis BCG complexed with poly-L-lysine and carboxymethylcellulose. Jpn J Med Sci Biol. 1990 Oct;43(5):171-82.	
	C236	KITAGAKI et al., Immunomodulatory effects of CpG oligodeoxynucleotides on established th2 responses. Clin Diagn Lab Immunol. 2002 Nov;9(6):1260-9.	
	C237	KLINMAN et al., Modulation of airway inflammation by CpG oligodeoxynucleotides in a murine model of asthma. J Immunol. 1998 Mar 15;160(6):2555-9.	
	C238	KLINMAN et al., Treatment of established asthma in a murine model using CpG oligodeoxynucleotides. Am J Physiol Lung Cell Mol Physiol. 2002 Jul;283(1):L170-9.	
	C239	KLINMAN et al., DNA therapy for asthma. Curr Opin Allergy Clin Immunol. 2002 Feb;2(1):69-73.	
	C240	KLINMAN et al., Effects of CpG DNA on Th1/Th2 balance in asthma. Curr Top Microbiol Immunol. 2000;247:211-25.	
	C241	KLINMAN et al., CpG oligodeoxynucleotides do not require TH1 cytokines to prevent eosinophilic airway inflammation in a murine model of asthma. J Allergy Clin Immunol. 1999 Dec;104(6):1258-64.	
	C242	KLINMAN et al., Therapeutic applications of CpG-containing oligodeoxynucleotides. Antisense Nucleic Acid Drug Dev. 1998 Apr;8(2):181-4.	
	C243	KLINMAN et al., Immunotherapeutic applications of CpG-containing oligodeoxynucleotides. Drug News Perspect. 2000 Jun;13(5):289-96.	
	C244	KLINMAN et al., CpG motifs as immune adjuvants. Vaccine. 1999 Jan;17(1):19-25.	
	C245	KRIEG et al., American College of Rheumatology 58 th National Scientific Meeting. Minneapolis, Minnesota, October 22, 1994. Abstracts. Arthritis Rheum. 1994 Sep;37(9 Suppl).	
	C246	KRIEG et al., Direct immunologic activities of CpG DNA and implications for gene therapy. J Gene Med. 1999 Jan-Feb;1(1):56-63.	
	C247	KRIEG et al., Applications of immune stimulatory CpG DNA for antigen-specific and antigen-nonspecific cancer immunotherapy. Eur J Canc. 1999 Oct; 35/Suppl4:S10. Abstract #14.	
	C248	KRIEG et al., Causing a commotion in the blood: immunotherapy progresses from bacteria to bacterial DNA. Immunol Today. 2000 Oct;21(10):521-6.	
	C249	KRIEG et al., Chapter 8: Immune Stimulation by Oligonucleotides. in Antisense Research and Application. Crooke, editor. 1998; 243-62.	
	C250	KRIEG et al., A role for endogenous retroviral sequences in the regulation of lymphocyte activation. J Immunol. 1989 Oct 15;143(8):2448-51.	
	C251	KRIEG et al., P-chirality-dependent immune activation by phosphorothioate CpG oligodeoxynucleotides. Oligonucleotides. 2003;13(6):491-9.	
	C252	KRIEG et al., Chapter 17: Immune stimulation by oligonucleotides. in Antisense Drug Tech. 2001;1394:471-515.	
NMM	C253	KRIEG et al., Mechanisms and applications of immune stimulatory CpG oligodeoxynucleotides. Biochim Biophys Acta. 1999 Dec 10;1489(1):107-16.	

EXAMINER:	DATE CONSIDERED:
/N. M. Minnifield/ (10/20/2006)	10/20/2006

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449/A and B (modified PTO/SB/08) INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICATION NO.: 10/735,592		ATTY. DOCKET NO.: C1037.70038US01	
				FILING DATE: December 11, 2003		CONFIRMATION NO.: 2533	
				APPLICANT: Krieg et al.			
				GROUP ART UNIT: 1645		EXAMINER: Nita M. Minnifield	
Sheet	11	of	14				

NMM	C254	KRIEG et al., The CpG motif: Implications for clinical immunology. BioDrugs. 1998 Nov 1;10(5):341-6.	
	C255	KRIEG et al., Mechanism of action of CpG DNA. Curr Top Microbiol Immunol. 2000;247:1-21.	
	C256	KRIEG et al., CpG DNA: a novel immunomodulator. Trends Microbiol. 1999 Feb;7(2):64-5.	
	C257	KRIEG, Signal transduction induced by immunostimulatory CpG DNA. Springer Semin Immunopathol. 2000;22(1-2):97-105.	
	C258	KRIEG et al., How to exclude immunostimulatory and other nonantisense effects of antisense oligonucleotides. Manual of Antisense. 1999:79-89.	
	C259	KRIEG et al., Unmethylated CpG DNA protects mice from lethal listeria monocytogenes challenge. Vaccines. 1997; 97:77-9.	
	C260	KRIEG et al., Infection. In McGraw Hill Book. 1996: 242-3.	
	C261	KRIEG et al., Lymphocyte activation by CpG dinucleotide motifs in prokaryotic DNA. Trends Microbiol. 1996 Feb;4(2):73-6.	
	C262	KRUG et al., Identification of CpG oligonucleotide sequences with high induction of IFN-alpha/beta in plasmacytoid dendritic cells. Eur J Immunol. 2001 Jul;31(7):2154-63.	
	C263	KRUG et al., Toll-like receptor expression reveals CpG DNA as a unique microbial stimulus for plasmacytoid dendritic cells which synergizes with CD40 ligand to induce high amounts of IL-12. Eur J Immunol. 2001 Oct;31(10):3026-37.	
	C264	KURAMOTO et al., Induction of T-cell-mediated immunity against MethA fibrosarcoma by intratumoral injections of a bacillus Calmette-Guerin nucleic acid fraction. Cancer Immunol Immunother. 1992;34(5):283-8.	
	C265	LIU et al., CpG directly induces T-bet expression and inhibits IgG1 and IgE switching in B cells. Nat Immunol. 2003 Jul;4(7):687-93.	
	C266	MacFARLANE et al., Unmethylated CpG-containing oligodeoxynucleotides inhibit apoptosis in WEHI 231 B lymphocytes induced by several agents: evidence for blockade of apoptosis at a distal signalling step. Immunology. 1997 Aug;91(4):586-93.	
	C267	MARSHALL et al., Immunostimulatory sequence DNA linked to the Amb a 1 allergen promotes T(H)1 cytokine expression while downregulating T(H)2 cytokine expression in PBMCs from human patients with ragweed allergy. J Allergy Clin Immunol. 2001 Aug;108(2):191-7.	
	C268	MARTIN-OROZCO et al., Enhancement of antigen-presenting cell surface molecules involved in cognate interactions by immunostimulatory DNA sequences. Int Immunol. 1999 Jul;11(7):1111-8.	
	C269	MESSINA et al., The influence of DNA structure on the in vitro stimulation of murine lymphocytes by natural and synthetic polynucleotide antigens. Cell Immunol. 1993 Mar;147(1):148-57.	
	C270	MUHLHAUSER et al., VEGF165 expressed by a replication-deficient recombinant adenovirus vector induces angiogenesis in vivo. Circ Res. 1995 Dec;77(6):1077-86.	
	C271	OCHIAI et al., Studies on lymphocyte subsets of regional lymph nodes after endoscopic injection of biological response modifiers in gastric cancer patients. Int J Immunotherapy. 1986;11(4):259-65.	
	C272	PARRONCHI et al., Phosphorothioate oligodeoxynucleotides promote the in vitro development of human allergen-specific CD4+ T cells into Th1 effectors. J Immunol. 1999 Dec 1;163(11):5946-53.	
	C273	PISETSKY et al., Immunological properties of bacterial DNA. Ann N Y Acad Sci. 1995 Nov 27;772:152-63.	
NMM	C274	PISETSKY et al., Influence of backbone chemistry on immune activation by synthetic oligonucleotides. Biochem Pharmacol. 1999 Dec 15;58(12):1981-8.	

EXAMINER: /N. M. Minnifield/ (10/20/2006)	DATE CONSIDERED: 10/20/2006
--	------------------------------------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449/A and B (modified PTO/SB/08) INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICATION NO.: 10/735,592		ATTY. DOCKET NO.: C1037.70038US01	
				FILING DATE: December 11, 2003		CONFIRMATION NO.: 2533	
				APPLICANT: Krieg et al.			
				GROUP ART UNIT: 1645		EXAMINER: Nita M. Minnifield	
Sheet	12	of	14				

NMM	C275	PISETSKY et al., Immune activation by bacterial DNA: a new genetic code. Immunity. 1996 Oct;5(4):303-10.	
	C276	PISETSKY et al., The influence of base sequence on the immunological properties of defined oligonucleotides. Immunopharmacology. 1998 Nov;40(3):199-208.	
	C277	POLANCZYK et al., Immunostimulatory effects of DNA and CpG motifs. Cent Eur J of Immunol. 2000;25(3):160-6.	
	C278	RANKIN et al., CpG motif identification for veterinary and laboratory species demonstrates that sequence recognition is highly conserved. Antisense Nucleic Acid Drug Dev. 2001 Oct;11(5):333-40.	
	C279	RANKIN et al., CpG-containing oligodeoxynucleotides augment and switch the immune responses of cattle to bovine herpesvirus-1 glycoprotein D. Vaccine. 2002 Jul 26;20(23-24):3014-22.	
	C280	RAZ et al., Potential role of immunostimulatory DNA sequences (ISS) in genetic immunization and autoimmunity. ACR Poster Session C: Cytokines and Inflammatory Mediators. 1996 Oct 20; Abstract Number 615.	
	C281	REDECKE et al., Cutting edge: activation of Toll-like receptor 2 induces a Th2 immune response and promotes experimental asthma. J Immunol. 2004 Mar 1;172(5):2739-43.	
	C282	ROTHENFUSSE et al., Recent advances in immunostimulatory CpG oligonucleotides. Curr Opin Mol Ther. 2003 Apr;5(2):98-106.	
	C283	SANDLER et al., CpG oligonucleotides enhance the tumor antigen-specific immune response of a granulocyte macrophage colony-stimulating factor-based vaccine strategy in neuroblastoma. Cancer Res. 2003 Jan 15;63(2):394-9.	
	C284	SANDRASAGRA et al., Discovery and development of respirable antisense therapeutics for asthma. Antisense Nucleic Acid Drug Dev. 2002 Jun;12(3):177-81.	
	C285	SANDS et al., Biodistribution and metabolism of internally 3H-labeled oligonucleotides. I. Comparison of a phosphodiester and a phosphorothioate. Mol Pharmacol. 1994 May;45(5):932-43.	
	C286	SINGH et al., Cationic microparticles are an effective delivery system for immune stimulatory CpG DNA. Pharm Res. 2001 Oct;18(10):1476-9.	
	C287	SPARWASSER et al., Bacterial DNA causes septic shock. Nature. 1997 Mar 27;386(6623):336-7.	
	C288	SPARWASSER et al., Immunostimulatory CpG-oligodeoxynucleotides cause extramedullary murine hemopoiesis. J Immunol. 1999 Feb 15;162(4):2368-74.	
	C289	SPIEGELBERG et al., DNA-based approaches to the treatment of allergies. Curr Opin Mol Ther. 2002 Feb;4(1):64-71.	
	C290	STEIN et al., Problems in interpretation of data derived from in vitro and in vivo use of antisense oligodeoxynucleotides. Antisense Res Dev. 1994 Summer;4(2):67-9.	
	C291	STEIN et al., Physicochemical properties of phosphorothioate oligodeoxynucleotides. Nucleic Acids Res. 1988 Apr 25;16(8):3209-21.	
	C292	STEIN et al., Non-antisense effects of oligodeoxynucleotides. Antisense Technology. 1997; ch11: 241-64.	
NMM	C293	STEIN et al., Antisense oligonucleotides as therapeutic agents--is the bullet really magical? Science. 1993 Aug 20;261(5124):1004-12.	

EXAMINER: /N. M. Minnifield/ (10/20/2006)	DATE CONSIDERED: 10/20/2006
--	--------------------------------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449/A and B (modified PTO/SB/08) INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICATION NO.: 10/735,592		ATTY. DOCKET NO.: C1037.70038US01	
				FILING DATE: December 11, 2003		CONFIRMATION NO.: 2533	
				APPLICANT: Krieg et al.			
				GROUP ART UNIT: 1645		EXAMINER: Nita M. Minnifield	
Sheet	13	of	14				

NMM	C294	STUNZ et al., Inhibitory oligonucleotides specifically block effects of stimulatory CpG oligonucleotides in B cells. Eur J Immunol. 2002 May;32(5):1212-22.	
	C295	SUR et al., Long term prevention of allergic lung inflammation in a mouse model of asthma by CpG oligodeoxynucleotides. J Immunol. 1999 May 15;162(10):6284-93.	
	C296	TANAKA et al., An antisense oligonucleotide complementary to a sequence in I gamma 2b increases gamma 2b germline transcripts, stimulates B cell DNA synthesis, and inhibits immunoglobulin secretion. J Exp Med. 1992 Feb 1;175(2):597-607.	
	C297	UHLMANN et al., Recent advances in the development of immunostimulatory oligonucleotides. Curr Opin Drug Discov Devel. 2003 Mar;6(2):204-17.	
	C298	VAN UDEN et al., Immunostimulatory DNA and applications to allergic disease. J Allergy Clin Immunol. 1999 Nov;104(5):902-10.	
	C299	VERTHELYI et al., Immunoregulatory activity of CpG oligonucleotides in humans and nonhuman primates. Clin Immunol. 2003 Oct;109(1):64-71.	
	C300	VERTHELYI et al., Human peripheral blood cells differentially recognize and respond to two distinct CPG motifs. J Immunol. 2001 Feb 15;166(4):2372-7.	
	C301	VOLLMER et al., Highly immunostimulatory CpG-free oligodeoxynucleotides for activation of human leukocytes. Antisense Nucleic Acid Drug Dev. 2002 Jun;12(3):165-75.	
	C302	VOLLMER et al., Immunopharmacology of CpG oligodeoxynucleotides and ribavirin. Antimicrob Agents Chemother. 2004 Jun;48(6):2314-7.	
	C303	VOLLMER et al., Characterization of three CpG oligodeoxynucleotide classes with distinct immunostimulatory activities. Eur J Immunol. 2004 Jan;34(1):251-62.	
	C304	VOLLMER et al., Modulation of CpG oligodeoxynucleotide-mediated immune stimulation by locked nucleic acid (LNA). Oligonucleotides. 2004 Spring;14(1):23-31.	
	C305	WANG et al., Synergy between CpG- or non-CpG DNA and specific antigen for B cell activation. Int Immunol. 2003 Feb;15(2):223-31.	
	C306	WHITESELL et al., Stability, clearance, and disposition of intraventricularly administered oligodeoxynucleotides: implications for therapeutic application within the central nervous system. Proc Natl Acad Sci U S A. 1993 May 15;90(10):4665-9.	
	C307	YAMAMOTO et al., [Commemorative lecture of receiving Imamura Memorial Prize. II. Mode of action of oligonucleotide fraction extracted from Mycobacterium bovis BCG] Kekkaku. 1994 Sep;69(9):571-4.	Abstract
	C308	YAMAMOTO et al., Synthetic oligonucleotides with certain palindromes stimulate interferon production of human peripheral blood lymphocytes in vitro. Jpn J Cancer Res. 1994 Aug;85(8):775-9.	
	C309	YI et al., CpG DNA rescue of murine B lymphoma cells from anti-IgM-induced growth arrest and programmed cell death is associated with increased expression of c-myc and bcl-xL. J Immunol. 1996 Dec 1;157(11):4918-25.	
	C310	YU et al., Accessible 5'-end of CpG-containing phosphorothioate oligodeoxynucleotides is essential for immunostimulatory activity. Bioorg Med Chem Lett. 2000 Dec 4;10(23):2585-8.	
NMM	C311	ZHAO et al., Pattern and kinetics of cytokine production following administration of phosphorothioate oligonucleotides in mice. Antisense Nucleic Acid Drug Dev. 1997 Oct;7(5):495-502.	

EXAMINER: /N. M. Minnifield/ (10/20/2006)	DATE CONSIDERED: 10/20/2006
--	--------------------------------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449/A and B (modified PTO/SB/08) INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICATION NO.: 10/735,592		ATTY. DOCKET NO.: C1037.70038US01			
				FILING DATE: December 11, 2003		CONFIRMATION NO.: 2533			
				APPLICANT: Krieg et al.					
				GROUP ART UNIT: 1645		EXAMINER: Nita M. Minnifield			
Sheet	14	of	14						

NMM	C312	ZHAO et al., Modulation of oligonucleotide-induced immune stimulation by cyclodextrin analogs. Biochem Pharmacol. 1996 Nov 22;52(10):1537-44.	
NMM	C313	ZHAO et al., Effect of different chemically modified oligodeoxynucleotides on immune stimulation. Biochem Pharmacol. 1996 Jan 26;51(2):173-82.	

*a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. __, filed __, and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).

[NOTE – No copies of U.S. patents, published U.S. patent applications, or pending, unpublished patent applications stored in the USPTO's Image File Wrapper (IFW) system, are included. See 37 CFR §1.98 and 1287OG163. Copies of all other patent(s), publication(s), unpublished, pending U.S. patent applications, or other information listed are provided as required by 37 CFR §1.98 unless 1) such copies were provided in an IDS in an earlier application that complies with 37 CFR §1.98, and 2) the earlier application is relied upon for an earlier filing date under 35 U.S.C. §120.]

EXAMINER: /N. M. Minnifield/ (10/20/2006)	DATE CONSIDERED: 10/20/2006
--	------------------------------------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICATION NO.: 10/735,592		ATTY. DOCKET NO.: C1037.70038US01	
				FILING DATE: December 11, 2003		CONFIRMATION NO.: 2533	
				APPLICANT: Krieg et al.			
				GROUP ART UNIT: 1645 1645		EXAMINER: N. V. ... MINNIFIELD	
Sheet	1	of	12				

U.S. PATENT DOCUMENTS

Examiner's Initials	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication or of issue of Cited Document MM-DD-YYYY
		Number	Kind Code		
NMM	A1**	5,023,243		Tullis	
	A2**	5,248,670		Draper, et al.	
	A3**	5,268,365		Rudolph, et al.	
	A4**	5,543,152		Webb, et al.	
	A5**	5,595,756		Bally, et al.	
	A6**	5,663,153		Hutcherson, et al.	
	A7**	5,679,647		Carson, et al.	
	A8**	5,705,385		Bally, et al.	
	A9**	5,723,335		Hutcherson, et al.	
	A10**	5,753,613		Ansell, et al.	
	A11**	5,756,097		Landucci, et al.	
	A12**	5,766,920		Babbitt, et al.	
	A13**	5,780,448		Davis	
	A14**	5,785,992		Ansell, et al.	
	A15**	5,786,189		Locht, et al.	
	A16**	5,804,566		Carson, et al.	
	A17**	5,814,335		Webb, et al.	
	A18**	5,837,243		Deo, et al.	
	A19**	5,849,719		Carson, et al.	
	A20**	5,932,556			
	A21**	5,965,542		Wasan, et al.	
	A22**	5,976,567		Wheeler, et al.	
	A23**	5,981,501		Wheeler, et al.	
	A24**	6,027,726		Ansell	
	A25**	6,110,745		Zhang, et al.	
	A26**	6,174,872		Carson, et al.	
	A27**	6,426,336	B1	Carson, et al.	
	A28**	6,498,148	B1	Raz	
	A29**	6,514,948	B1	Raz, et al.	
	A30**	6,534,062		Raz, et al.	
	A31**	6,544,518		Friede, et al.	
	A32**	6,552,006	B2	Raz, et al.	
	A33**	6,562,798	B1	Schwartz	05-13-2003
	A34**	6,589,940	B1	Raz, et al.	
	A35**	6,610,661		Carson, et al.	08-26-2003
↓	A36**	2001/0034330		Kensil	
NMM	A37**	2001/0036462		Fong et al.	

FORM PTO-1449/A and B (Modified) INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICATION NO.: 10/735,592		ATTY. DOCKET NO.: C1037.70038US01	
				FILING DATE: December 11, 2003		CONFIRMATION NO.: 2533	
				APPLICANT: Krieg et al.			
				GROUP ART UNIT: 1645		EXAMINER: MINNIFIELD	
Sheet	2	of	12				

NMM	A38**	2003/0072762		Van de Winkel et al.	
	A39**	2003/0119774		Foldvari et al.	
	A40**	2003/0125279		Junghans et al.	
	A41**	2003/0125292		Semple et al.	
	A42**	2003/0138413	A1	Vicari et al.	
	A43**	2003/0186912		Agrawal	
	A44**	6,194,388	B1	Krieg et al.	
	A45**	6,207,646	B1	Krieg et al.	03-27-2001
	A46**	6,214,806	B1	Krieg et al.	04-10-2001
	A47**	6,218,371	B1	Krieg et al.	04-17-2001
	A48**	6,239,116	B1	Krieg et al.	05-29-2001
	A49**	6,339,068	B1	Krieg et al.	01-15-2002
	A50**	6,406,705	B1	Davis et al.	06-18-2002
	A51**	6,429,199	B1	Krieg et al.	08-06-2002
	A52**	6,653,292	B1	Krieg et al.	11-25-2003
	A53**	6,727,230	B1	Hutcherson et al.	04-27-2004
	A54**	2001/0044416	A1	McCluskie et al.	11-22-2001
	A55**	2002/0064515	A1	Krieg et al.	05-30-2002
	A56**	2002/0091097	A1	Bratzler et al.	07-11-2002
	A57**	2002/0156033	A1	Bratzler et al.	10-24-2002
	A58**	2002/0165178	A1	Schetter et al.	11-07-2002
	A59**	2002/0164341	A1	Davis et al.	11-07-2002
	A60**	2002/0198165	A1	Bratzler et al.	12-26-2002
	A61**	2003/0026782	A1	Krieg et al.	02-06-2003
	A62**	2003/0026801	A1	Weiner et al.	02-06-2003
	A63**	2003/0050261	A1	Krieg et al.	03-13-2003
	A64**	2003/0050263	A1	Krieg et al.	03-13-2003
	A65**	2003/0050268	A1	Krieg et al.	03-13-2003
	A66**	2003/0055014	A1	Bratzler	03-20-2003
	A67**	2003/0087848	A1	Bratzler et al.	05-08-2003
	A68**	2003/0091599	A1	Davis et al.	05-15-2003
	A69**	2003/0100527	A1	Krieg et al.	05-29-2003
	A70**	2003/0104523	A1	Bauer et al.	06-05-2003
	A71**	2003/0139364	A1	Krieg et al.	07-24-2003
	A72**	2003/0148316	A1	Lipford et al.	08-07-2003
	A73**	2003/0148976	A1	Krieg et al.	08-07-2003
	A74**	2003/0166001	A1	Lipford	09-04-2003
	A75**	2003/0181406	A1	Schetter et al.	09-25-2003
	A76**	2003/0191079	A1	Krieg et al.	10-09-2003
	A77**	2003/0232074	A1	Lipford et al.	12-18-2003
V NMM	A78**	2004/0009949	A1	Krieg	01-15-2004

FORM PTO-1449/A and B (Modified) INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICATION NO.: 10/735,592		ATTY. DOCKET NO.: C1037.70038US01	
				FILING DATE: December 11, 2003		CONFIRMATION NO.: 2533	
				APPLICANT: Krieg et al.			
				GROUP ART UNIT: 1645		EXAMINER: MINNIFIELD	
Sheet	3	of	12				

NMM	A79**	6,613,751			09-02-2003
	A80**	2002/0028784			03-07-2002
	A81**	2001/0046967			11-29-2001
	A82**	2002/0042387			04-11-2002
	A83**	2002/0055477			
	A84**	2002/0098199			07-25-2002
	A85**	2002/0107212			
	A86**	2003/0022852			01-30-2003
	A87**	2003/0059773			03-27-2003
	A88**	2003/0078223			04-24-2003
	A89**	2003/0092663			05-15-2003
	A90**	2003/0119773			
	A91**	2003/0129251			
	A92**	2003/0130217			07-10-2003
	A93**	2003/0133988			07-17-2003
	A94**	2003/0175731			09-18-2003
	A95**	2003/0176389			09-18-2003
	A96**	2003/0199466			10-23-2003
	A97**	2003/0216340			
	A98**	2003/0225016			12-04-2003
	A99**	2003/0232780			12-18-2003
	A100**	2004/0006010			
	A101**	2004/0006034			01-08-2004
NMM	A102**	2004/0009942			01-15-2004

FOREIGN PATENT DOCUMENTS

Examiner's Initials	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document (not necessary)	Date of Publication of Cited Document MM-DD-YYYY	Translation (Y/N)
		Office/ Country	Number	Kind Code			
NMM	B1	EP	0 302 758	A1	New England Medical Center Hospitals, Inc.		
	B2	EP	0 468 520		Mitsui Toatsu Chemicals, Inc.		
	B3	WO	91/12811	A1	ISIS Pharmaceuticals Inc.		
	B4	WO	92/03456				
	B5	WO	94/19945	A1	ISIS Pharmaceuticals Inc.		
	B6	WO	96/24380		ICN Pharmaceuticals		
	B7	WO	97/28259	A1	The Regents of the University of California		
	B8	WO	98/16247	A1	The Regents of the University of California		
	B9	WO	98/29430		ICN Pharmaceuticals		
	B10	WO	98/32462				
	B11	WO	98/40100	A1	Ottawa Civic Loeb Research Institute		
NMM	B12	WO	98/51278	A2	INEX Pharmaceuticals Corp.		

FORM PTO-1449/A and B (Modified) INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICATION NO.: 10/735,592		ATTY. DOCKET NO.: C1037.70038US01			
				FILING DATE: December 11, 2003		CONFIRMATION NO.: 2533			
				APPLICANT: Krieg et al.					
				GROUP ART UNIT: 1042 1045		EXAMINER: MINNIFIELD MINNIFIELD			
Sheet	4	of	12						

NMM	B13	WO	98/55495	A2	Dynavax Technologies Corporation		
	B14	WO	99/11275	A2	The Regents of the University of California		
	B15	WO	99/30686				
	B16	WO	99/33493	A1	INEX Pharmaceuticals Corporation		
	B17	WO	99/52549				
	B18	WO	99/55743	A1	INEX Pharmaceuticals Corporation		
	B19	WO	99/62923	A2	Dynavax Technologies Corporation		
	B20	WO	00/03683	A2	INEX Pharmaceuticals Corporation		
	B21	WO	00/06588	A1	University of Iowa Research Foundation		
	B22	WO	00/16804	A1	Dynavax Technologies Corporation		
	B23	WO	00/20039	A1	The Regents of the University of California		
	B24	WO	00/21556	A1	Dynavax Technologies Corporation		
	B25	WO	00/62787	A1	The Regents of the University of California		
	B26	WO	01/02007	A1	The Regents of the University of California		
	B27	WO	01/12223	A2	Dynavax Technologies Corporation		
	B28	WO	01/12804	A2	Hybridon, Inc.		
	B29	WO	01/68077	A2	Dynavax Technologies Corporation		
	B30	WO	01/68078	A2	Dynavax Technologies Corporation		
	B31	WO	01/68103	A2	Dynavax Technologies Corporation		
	B32	WO	01/68116	A2	Dynavax Technologies Corporation		
	B33	WO	01/68117	A2	Dynavax Technologies Corporation		
	B34	WO	01/68143	A2	Dynavax Technologies Corporation		
	B35	WO	01/68144	A2	Dynavax Technologies Corporation		
	B36	WO	02/097478				
	B37	WO	02/102307	A2	Ribapharm		
	B38	WO	02/24225				
	B39	WO	02/26757	A2	Hybridon, Inc.		
	B40	WO	03/020889	A2	3M Innovative Properties Company		
	B41	WO	03/024481	A2	Cytos Biotechnology AG		
	B42	WO	03/030656				
	B43	WO	03/030934				
	B44	WO	03/045428	A2	Medigene Aktiengesellschaft		Y- Abstract Only
	B45	WO	03/094963				
V	B46	WO	03/100040	A1	Merck Patent GMBH		
NMM	B47	WO	03/101375				

FORM PTO-1449/A and B (Modified)				APPLICATION NO.: 10/735,592	ATTY. DOCKET NO.: C1037.70038US01
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				FILING DATE: December 11, 2003	CONFIRMATION NO.: 2533
				APPLICANT: Krieg et al.	
				GROUP ART UNIT: 1645 1645	EXAMINER: MINNIFIELD MINNIFIELD
Sheet	5	of	12		

OTHER ART — NON PATENT LITERATURE DOCUMENTS

Examiner's Initials	Cite No	Include name of the author (in CAPITAL LETTERS) title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, relevant page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)
NMM	C1	AGRAWAL et al., "Antisense oligonucleotides: towards clinical trials", <i>Trends in Biotechnology</i> , 14: 376-387, 1996.	
	C2	ANDERSON et al., "Induction of determinant spreading and of Th1 responses by in vitro stimulation with HER-2 peptides", <i>Cancer Immunology Immunotherapy</i> , 49(9): 459-68, 2000.	
	C3	ANDERSON et al., "TH2 and 'TH2-like' cells in allergy and asthma: pharmacological perspectives", <i>Trends in Pharmacological Science</i> , 15: 324-332, 1994.	
	C4	ASKEW et al., "CpG DNA induces maturation of dendritic cells with distinct effects on nascent and recycling MHC-II antigen-processing mechanisms", <i>Journal of Immunology</i> , 165: 6889-95, 2000.	
	C5	BALLAS et al., "Induction of NK activity in murine and human cells by CpG motifs in oligodeoxynucleotides and bacterial DNA", <i>J Immunol.</i> 1996 Sep 1;157(5):1840-5.	
	C6	BATES et al., "Antiproliferative activity of G-rich oligonucleotides correlates with protein binding", <i>Journal of Biological Chemistry</i> , 274: 26369-77, 1999.	
	C7	BAYEVER et al., "Systemic administration of a phosphorothioate oligonucleotide with a sequence complementary to p53 for acute myelogenous leukemia and myelodysplastic syndrome: initial results of a phase I trial", <i>Antisense Research & Development</i> , 3: 383-390, 1993.	
	C8	BENIMETSKAYA et al., "Formation of a G-tetrad and higher order structures correlates with biological activity of the RelA (NF-kappaB p65) 'antisense' oligodeoxynucleotide", <i>Nucleic Acid Research</i> , 25(3): 2648-56, 1997.	
	C9	BISHOP et al., "Intramolecular G-quartet motifs confer nuclease resistance to a potent anti-HIV oligonucleotide", <i>Journal of Biological Chemistry</i> , 271: 5698-5703, 1996.	
	C10	BLAXTER et al., "Genes expressed in <i>Brugia malayi</i> infective third stage larvae", <i>Molecular and Biochemical Parasitology</i> , 77: 77-93, 1996.	
	C11	BOGGS et al., "Characterization and modulation of immune stimulation by modified oligonucleotides", <i>Antisense Nucleic Acid Drug Development</i> , 7(5): 461-71, 1997.	
	C12	BRANDA et al., "Immune stimulation by an antisense oligomer complementary to the rev gene of HIV-1", <i>Biochemical Pharmacology</i> , 45(10): 2037-2043, 1993.	
	C13	BRANDA et al., "Amplification of antibody production by phosphorothioate oligodeoxynucleotides", <i>Journal of Laboratory Clinical Medicine</i> , 128(3): 329-38, 1996.	
	C14	BRAZOLOT-MILLAN et al., "CpG DNA can induce strong Th1 humoral and cell-mediated immune responses against hepatitis B surface antigen in young mice", <i>Proceedings of the National Academy of Science USA</i> , 95: 15553-15558, 1998.	
	C15	BROIDE et al., "DNA-Based immunization for asthma", <i>International Archives of Allergy and Immunology</i> , 118: 453-456, 1999.	
	C16	BROSSART et al., "Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells", <i>Blood</i> , 96(9): 3102-8, 2000.	
	C17	BRUNNER et al., "Enhanced dendritic cell maturation by TNF-alpha or cytidine-phosphate-guanosine DNA drives T cell activation in vitro and therapeutic anti-tumor immune responses in vivo", <i>Journal of Immunology</i> , 165: 6278-6286, 2000.	
	C18	BURGESS et al., "The antiproliferative activity of c-myc and c-myc antisense oligonucleotides in smooth muscle cells is caused by a nonantisense mechanism", <i>Proceedings of the National Academy of Science USA</i> , 92(9): 4051-5, 1995.	
	C19	CAVACINI et al., "Evidence of determinant spreading in the antibody responses to prostate cell surface antigens in patients immunized with prostate-specific antigen", <i>Clinical Cancer Research</i> , 8(2): 368-73, 2002.	
	C20	CHOI et al., "The level of protection against rotavirus shedding in mice following immunization with a chimeric VP6 protein is dependent on the route and the coadministered adjuvant", <i>Vaccine</i> , 20(13-14): 1733-40, 2002.	
	C21	CHU et al., "CpG oligodeoxynucleotides act as adjuvants that switch on T helper 1 (Th1) immunity", <i>Journal of Experimental Medicine</i> , 186(10): 1623-31, 1997.	
	C22	CONSTANT et al., "Induction of Th1 and Th2 CD4+ T cell responses: the alternative approaches", <i>Annual Reviews in Immunology</i> , 15: 297-322, 1997.	
	C23	CONSTANT et al., "Stimulation of human gamma delta T cells by nonpeptidic mycobacterial ligands", <i>Science</i> , 264: 267-70, 1994.	
NMM	C24	COSSUM et al., "Pharmacokinetics of a 14C-labeled phosphorothioate oligonucleotide, ISIS 2105, after intradermal administration to rats", <i>Journal of Pharmacological Experimental Theory</i> , 269(1): 89-94, 1994.	

FORM PTO-1449/A and B (Modified)		APPLICATION NO.: 10/735,592	ATTY. DOCKET NO.: C1037.70038US01
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		FILING DATE: December 11, 2003	CONFIRMATION NO.: 2533
		APPLICANT: Krieg et al.	
		GROUP ART UNIT: 1645	EXAMINER: MINNIFELD
Sheet	6	of	12

NMM	C25	COWDERY et al., "Bacterial DNA induces NK cells to produce IFN-gamma in vivo and increases the toxicity of lipopolysaccharides", <i>Journal of Immunology</i> , 156(12): 4570-5, 1996.		
	C26	COWSERT et al., "In vitro evaluation of phosphorothioate oligonucleotides targeted to the E2 mRNA of papillomavirus: potential treatment for genital warts", <i>Antimicrobial Agents in Chemotherapy</i> , 37: 171-77, 1993.		
	C27	DAHESHIA et al., "Immune induction and modulation by topical ocular administration of plasmid DNA encoding antigens and cytokines", <i>Vaccine</i> , 16(11-12): 1103-1110, 1998.		
	C28	DAPIC et al., <i>Proceedings of AACR</i> , pp. 42 March 2001.		
	C29	DAVIS et al., "CpG DNA is a potent enhancer of specific immunity in mice immunized with recombinant hepatitis B surface antigen", <i>Journal of Immunology</i> , 160(2): 870-6, 1998.		
	C30	DAVIS et al., "CpG DNA overcomes hyporesponsiveness to hepatitis B vaccine in orangutans", <i>Vaccine</i> , 18; 1920-1924, 2000.		
	C31	DAVIS et al., "Plasmid DNA expression systems for the purpose of immunization", <i>Current Opinions Biotechnology</i> , 8(5): 635-46, 1997.		
	C32	DAVIS et al., "Use of CpG DNA for enhancing specific immune responses", <i>Current Topics in Microbiology Immunology</i> , 247: 171-83, 2000.		
	C33	DEML et al., "Immunostimulatory CpG motifs trigger a T helper-1 immune response to human immunodeficiency virus type-1 (HIV-1) gp 160 envelope proteins", <i>Clinical Chemistry Laboratory Medicine</i> , 37: 199-204 1999.		
	C34	DIAMANTSTEIN et al., "Specific binding of poly(I)-poly(C) to the membrane of murine B lymphocyte subsets", <i>European Journal of Immunology</i> , 8: 896, 1978.		
	C35	DISIS et al., "Generation of immunity to the HER-2/neu oncogenic protein in patients with breast and ovarian cancer using a peptide-based vaccine", <i>Clinical Cancer Research</i> , 5(6): 1289-97, 1999.		
	C36	DISIS et al., "Generation of T-cell immunity to the HER-2/neu protein after active immunization with HER-2/neu peptide-based vaccines", <i>Journal of Clinical Oncology</i> , 20(11): 2624-32, 2002.		
	C37	DUMAIS et al., "Mucosal immunization with inactivated human immunodeficiency virus plus CpG oligodeoxynucleotides induces genital immune responses and protection against intravaginal challenge", <i>Journal of Infection and Disease</i> , 186(8): 1098-105, 2002.		
	C38	ELKINS et al., "Bacterial DNA containing CpG motifs stimulates lymphocyte-dependent protection of mice against lethal infection with intracellular bacteria", <i>Journal of Immunology</i> , 162: 2291-2298, 1999.		
	C39	EL-SHAMI et al., "MHC class I-restricted epitope spreading in the context of tumor rejection following vaccination with a single immunodominant CTL epitope", <i>European Journal of Immunology</i> , 29(10): 3295-301, 2002.		
	C40	EWEL et al., "Polyinosinic-polycytidylic acid complexed with poly-L-lysine and carboxymethylcellulose in combination with interleukin 2 in patients with cancer: clinical and immunological effects", <i>Cancer Research</i> , 52(11): 3005-10, 1992.		
	C41	FREIDAG et al., "CpG oligodeoxynucleotides and interleukin-12 improve the efficacy of Mycobacterium bovis BCG vaccination in mice challenged with M. tuberculosis", <i>Infection and Immunity</i> , 68: 2948-2953, 2000.		
	C42	GALLICHAN et al., "Intranasal immunization with CpG oligodeoxynucleotides as an adjuvant dramatically increases IgA and protection against herpes simplex virus-2 in the genital tract", <i>The Journal of Immunology</i> , 166: 3451-3457, 2001.		
	C43	HADDEN et al., "Immunostimulants", <i>Trends in Pharmacological Science</i> , 14: 169-174, 1993.		
	C44	HAHM et al., "Efficacy of polyadenylic-polyuridylic acid in the treatment of chronic active Hepatitis B", <i>Int J Immunopharmac</i> , 16(3): 217-25, 1994.		
	C45	HALPERN et al., "Bacterial DNA induces murine interferon-gamma production by stimulation of interleukin-12 and tumor necrosis factor-alpha", <i>Cell Immunology</i> , 167(1): 72-8, 1996.		
	C46	HARRINGTON et al., "Adjuvant effects of low doses of a nuclease-resistant derivative of polyinosinic acid . polycytidylic acid on antibody responses of monkeys to inactivated Venezuelan equine encephalomyelitis virus vaccine", <i>Infection and Immunity</i> , 24: 160, 1979.		
	C47	HARTMANN et al., "CpG DNA and LPS induce distinct patterns of activation in human monocytes", <i>Gene Therapy</i> , 6: 893-903, 1999.		
	C48	HARTMANN et al., "Mechanism and function of a newly identified CpG DNA motif in human primary B cells", <i>Journal of Immunology</i> , 164: 944, 2000.		
NMM	C49	HARTMANN et al., "Specific suppression of human tumor necrosis factor-alpha synthesis by antisense oligodeoxynucleotides", <i>Antisense Nucleic Acid Drug Development</i> , 6: 291, 1996.		

FORM PTO-1449/A and B (Modified) INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICATION NO.: 10/735,592		ATTY. DOCKET NO.: C1037.70038US01	
				FILING DATE: December 11, 2003		CONFIRMATION NO.: 2533	
				APPLICANT: Krieg et al.			
				GROUP ART UNIT: 1645 1645		EXAMINER: MINNIFIELD MINNIFIELD	
Sheet	7	of	12				

NMM			
	C50	HARTMANN et al., "Delineation of a CpG phosphorothioate oligodeoxynucleotide for activating primate immune responses in vitro and in vivo", <i>Journal of Immunology</i> , 164: 1617, 2000.	
	C51	HARTMANN et al., "CpG DNA: a potent signal for growth, activation, and maturation of human dendritic cells", <i>Proceedings of the National Academy of Science USA</i> , 96: 9305-9310, 1999.	
	C52	HAYASHI et al., "Enhancement of innate immunity against Mycobacterium avium infection by immunostimulatory DNA is mediated by indoleamine 2,3-dioxygenase", <i>Infection and Immunity</i> , 69: 6156-6164, 2001.	
	C53	HINKULA et al., "Recognition of prominent viral epitopes induced by immunization with human immunodeficiency virus type 1 regulatory genes", <i>Journal of Virology</i> , 71(7): 5528-39, 1997.	
	C54	HOPKIN et al., <i>BioMedNet</i> , Issue 57, 6/25/1999.	
	C55	HUANG et al., "Induction and regulation of Th1-inducing cytokines by bacterial DNA, lipopolysaccharide, and heat-inactivated bacteria", <i>Infection and Immunity</i> , 67(12): 6257-6263, 1999.	
	C56	HUGHES et al., <i>Antisense Research Development</i> , 4: 211-15, 1994.	
	C57	HUNG et al., "Improving vaccine potency through intercellular spreading and enhanced MHC class I presentation of antigen", <i>Journal of Immunology</i> , 166(9): 5733-40, 2001.	
	C58	IHO et al., "Oligodeoxynucleotides containing palindrome sequences with internal 5'-CpG-3' act directly on human NK and activated T cells to induce IFN-gamma production in vitro", <i>Journal of Immunology</i> , 163: 3642, 1999.	
	C59	ISHIKAWA et al., "IFN induction and associated changes in splenic leukocyte distribution", <i>Journal of Immunology</i> , 150(9): 3713-27, 1993.	
	C60	IVERSEN et al., "Pharmacokinetics of an antisense phosphorothioate oligodeoxynucleotide against rev from human immunodeficiency virus type 1 in the adult male rat following single injections and continuous infusion", <i>Antisense Research and Development</i> , 4: 43-52, 1994.	
	C61	JAKOB et al., "Activation of cutaneous dendritic cells by CpG-containing oligodeoxynucleotides: a role for dendritic cells in the augmentation of Th1 responses by immunostimulatory DNA", <i>Journal of Immunology</i> , 161(6): 3042-9, 1998.	
	C62	JAKOB et al., "Bacterial DNA and CpG-containing oligodeoxynucleotides activate cutaneous dendritic cells and induce IL-12 production: implications for the augmentation of Th1 responses", <i>International Archives of Allergy Immunology</i> , 118(2-4): 457-61, 1999.	
	C63	JOHNSON et al., <i>Immunopharmacology, Infection, and Disease</i> , 291-301, 1987.	
	C64	JONES et al., "Synthetic oligodeoxynucleotides containing CpG motifs enhance immunogenicity of a peptide malaria vaccine in Aotus monkeys", <i>Vaccine</i> , 17: 3065-3071, 1999.	
	C65	JUFFERMANS et al., "CpG oligodeoxynucleotides enhance host defense during murine tuberculosis", <i>Infection and Immunity</i> , 70: 147-152, 2002.	
	C66	KANDIMALLA et al., "A dinucleotide motif in oligonucleotides shows potent immunomodulatory activity and overrides species-specific recognition observed with CpG motif", <i>Proceedings of the National Academy of Science</i> , 100(24): 14303-14308, 2003.	
	C67	KATAOKA et al., "Antitumor activity of synthetic oligonucleotides with sequences from cDNA encoding proteins of Mycobacterium bovis BCG", <i>Japan Journal of Cancer Research</i> , 83: 244-247, 1992.	
	C68	KERN et al., "Herpesvirus hominis infection in newborn mice: treatment with interferon inducer polyinosinic-polycytidylic acid", <i>Antimicrobial Agent Chemotherapy</i> , 7: 793, 1975.	
	C69	KIMURA et al., "Binding of oligoguanylate to scavenger receptors is required for oligonucleotides to augment NK cell activity and induce IFN", <i>Journal of Biochemistry</i> , 116(5): 991-994, 1994.	
	C70	KLINNE et al., <i>Journal of Investigative Medicine</i> , 44(7): 380A, 1996.	
	C71	KLINNE et al., <i>Journal of Investigative Medicine</i> , 45(3): 282A, 1997.	
	C72	KLINNE et al., <i>Journal of Investigative Medicine</i> , 45(7): 298A, 1997.	
	C73	KLINNE et al., "CpG oligodeoxynucleotides do not require TH1 cytokines to prevent eosinophilic airway inflammation in a murine model of asthma", <i>Journal of Allergy and Clinical Immunology</i> , 1258-64, 1999.	
	C74	KLINMAN et al., "Immune recognition of foreign DNA: a cure for bioterrorism?", <i>Immunity</i> , 11: 123-129, 1999.	
	C75	KLINMAN et al., "Repeated administration of synthetic oligodeoxynucleotides expressing CpG motifs provides long-term protection against bacterial infection", <i>Infection and Immunity</i> , 67: 5658-5663, 1999.	
NMM	C76	KLINMAN et al., "Activation of the innate immune system by CpG oligodeoxynucleotides: immunoprotective activity and safety", <i>Springer Seminars in Immunopathology</i> , 22: 173-183, 2000.	

FORM PTO-1449/A and B (Modified)				APPLICATION NO.: 10/735,592		ATTY. DOCKET NO.: C1037.70038US01			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				FILING DATE: December 11, 2003		CONFIRMATION NO.: 2533			
				APPLICANT: Krieg et al.					
				GROUP ART UNIT: 1645		EXAMINER: MINNIFIELD			
Sheet	8	of	12						

NMM			
	C77	KLINMAN et al., "Contribution of CpG motifs to the immunogenicity of DNA vaccines", <i>Journal of Immunology</i> , 158(8): 3635-9, 1997.	
	C78	KLINMAN et al., "CpG motifs present in bacteria DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, and interferon gamma", <i>Proceedings of the National Academy of Science USA</i> , 93(7): 2879-83, 1996.	
	C79	KOU et al., <i>Arerugi</i> , 43: 482, 1994. Abstract only	
	C80	KOVARIK et al., "Adjuvant effects of CpG oligodeoxynucleotides on responses against T-independent type 2 antigens", <i>Immunology</i> , 102(1): 67-76, 2001.	
	C81	KOVARIK et al., <i>The Journal of Immunology</i> , 162: 1611-1617, 1999.	
	C82	KRANZER et al., "CpG oligodeoxynucleotides can circumvent the Th2 polarization of neonatal responses to vaccines but may fail to fully redirect Th2 responses established by neonatal priming", <i>Immunology</i> , 99: 170, 2000.	
	C83	KRIEG et al., "CpG motifs in bacterial DNA and their immune effects", <i>Annual Reviews in Immunology</i> , 20: 709, 2002.	
	C84	KRIEG et al., "Immune effects and therapeutic applications of CpG motifs in bacterial DNA", <i>Immunopharmacology</i> , 48: 303-305, 2000.	
	C85	KRIEG et al., "Oligodeoxynucleotide modifications determine the magnitude of B cell stimulation by CpG motifs", <i>Antisense Nucleic Acid Drug Development</i> , 6(2): 133-9, 1996.	
	C86	KRIEG et al., "Phosphorothioate oligodeoxynucleotides: antisense or anti-protein?", <i>Antisense Research and Development</i> , 5: 241, 1995.	
	C87	KRIEG et al., <i>Applied Antisense Oligonucleotide Technology</i> , 431-448, 1998.	
	C88	KRIEG et al., "CpG DNA: a pathogenic factor in systemic lupus erythematosus?", <i>Journal of Clinical Immunology</i> , 15(6): 284-292, 1995.	
	C89	KRIEG et al., "CpG motifs in bacterial DNA trigger direct B-cell activation", <i>Nature</i> , 374: 546-9, 1995.	
	C90	KRIEG et al., "Modification of antisense phosphodiester oligodeoxynucleotides by a 5' cholesteryl moiety increases cellular association and improves efficacy", <i>Proceedings of the National Academy of Science</i> , 90: 1048-1052, 1993.	
	C91	KRIEG et al., "The role of CpG dinucleotides in DNA vaccines", <i>Trends in Microbiology</i> , 6: 23-27, 1998.	
	C92	KRIEG et al., "An innate immune defense mechanism based on the recognition of CpG motifs in microbial DNA", <i>Journal of Laboratory Clinical Medicine</i> , 128(2): 128-33, 1996.	
	C93	KRIEG et al., Abstract from 1996 meeting on Molecular Approaches to the Control of Infectious Diseases, Cold Spring Harbor Laboratory, September 9-13, 1996. p.116.	
	C94	KRIEG et al., "Enhancing vaccines with immune stimulatory CpG DNA", <i>Current Opinions Molecular Theory</i> , 3(1): 15-24, 2001.	
	C95	KRIEG et al., "CpG oligonucleotides as immune adjuvants", Ernst Schering Res Found Workshop: 2000;(30):105-18. Review.	
	C96	KRIEG et al., "Immune effects and mechanisms of action of CpG motifs", <i>Vaccine</i> , 19(6): 618-22, 2001.	
	C97	KRIEG et al., "The role of CpG motifs in innate immunity", <i>Current Opinions Immunology</i> , 12: 35, 2000.	
	C98	KRIEG et al., "Mechanism of Action in CpG DNA", <i>Current Topics in Microbiology and Immunology</i> , 247: 1-21, 2000.	
	C99	KRIEG et al., "Mechanisms and therapeutic applications of immune stimulatory cpG DNA", <i>Pharmacological Theory</i> , 84: 113, 1999.	
	C100	KRIEG et al., "Sequence motifs in adenoviral DNA block immune activation by stimulatory CpG motifs", <i>Proceedings of the National Academy of Science</i> , 95: 12631-636, 1998.	
	C101	KRIEG et al., "CpG DNA induces sustained IL-12 expression in vivo and resistance to <i>Listeria monocytogenes</i> challenge", <i>Journal of Immunology</i> , 161(5): 2428-2434, 1998.	
	C102	KROWN et al., <i>Journal of Interferon Research</i> , 3: 281, 1983.	
	C103	KROWN et al., "Interferons and interferon inducers in cancer treatment", <i>Seminars in Oncology</i> , 13(2): 207-17, 1986.	
	C104	KURAMOTO et al., "Changes of host cell infiltration into Meth A fibrosarcoma tumor during the course of regression induced by injections of a BCG nucleic acid fraction", <i>International Immunopharmacology</i> , 14(5): 773-782, 1992.	
NMM	C105	KURAMOTO et al., "Oligonucleotide sequences required for natural killer cell activation", <i>Japan Journal of Cancer Research</i> , 83: 1128-1131, 1992.	

FORM PTO-1449/A and B (Modified)				APPLICATION NO.: 10/735,592		ATTY. DOCKET NO.: C1037.70038US01			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				FILING DATE: December 11, 2003		CONFIRMATION NO.: 2533			
				APPLICANT: Krieg et al.					
				GROUP ART UNIT: 1645 1645		EXAMINER: XXXXXXXXXX MINNIFIELD			
Sheet	9	of	12						

NMM			
	C106	KURAMOTO et al., "In situ infiltration of natural killer-like cells induced by intradermal injection of the nucleic acid fraction from BCG", <i>Microbiological Immunology</i> , 33(11): 929-940, 1989.	
	C107	LALLY et al., "Unmasking cryptic epitopes after loss of immunodominant tumor antigen expression through epitope spreading", <i>International Journal of Cancer</i> , 93(6): 841-7, 2001.	
	C108	LEDERMAN et al., "Polydeoxyguanine motifs in a 12-mer phosphorothioate oligodeoxynucleotide augment binding to the v3 loop of HIV-1 gp120 and potency of HIV-1 inhibition independency of G-tetrad formation", <i>Antisense Nucleic Acid Drug Development</i> , 6: 281-9, 1996.	
	C109	LEE et al., "An oligonucleotide blocks interferon-gamma signal transduction", <i>Transplantation</i> , 62: 1297-1301, 1996.	
	C110	LEONARD et al., "Conformation of guanine-8-oxoadenine base pairs in the crystal structure of d(CGCGAATT(O8A)GCG)", <i>Biochemistry</i> , 31(36): 8415-8420, 1992.	
	C111	LEVINE et al., "Phase I-II trials of poly IC stabilized with poly-L-lysine", <i>Cancer Treatment Reports</i> , 62: 1907, 1978.	
	C112	LEVY et al., <i>Journal of Infectious Disease</i> , 133: A256, 1976.	
	C113	LIAU et al., "Tumor immunity within the central nervous system stimulated by recombinant Listeria monocytogenes vaccination", <i>Cancer Research</i> , 62(8): 2287-93, 2002.	
	C114	LIPFORD et al., "CpG-containing synthetic oligonucleotides promote B and cytotoxic T cell responses to protein antigen: a new class of vaccine adjuvants", <i>European Journal of Immunology</i> , 27(9): 2340-4, 1997.	
	C115	LIPFORD et al., "Immunostimulatory DNA: sequence-dependent production of potentially harmful or useful cytokines", <i>European Journal of Immunology</i> , 27: 3420-6, 1997.	
	C116	LIPFORD et al., "Bacterial DNA as immune cell activator", <i>Trends Microbiological</i> , 6(12): 496-500, 1998.	
	C117	LIU et al., "Immunostimulatory CpG oligodeoxynucleotides enhance the immune response to vaccine strategies involving granulocyte-macrophage colony-stimulating factor", <i>Blood</i> , 92(10): 3730-3736, 1998.	
	C118	LOKE et al., "Delivery of c-myc antisense phosphorothioate oligodeoxynucleotides to hematopoietic cells in culture by liposome fusion: specific reduction in c-myc protein expression correlates with inhibition of cell growth and DNA synthesis", <i>Current Topics Microbiological Immunology</i> , 141: 282, 1988.	
	C119	MACAYA et al., "Thrombin-binding DNA aptamer forms a unimolecular quadruplex structure in solution", <i>Proceedings of the National Academy of Science</i> , 90: 3745-9, 1993.	
	C120	MALANCHERE-BRES et al., "CpG oligodeoxynucleotides with hepatitis B surface antigen (HBsAg) for vaccination in HBsAg-transgenic mice", <i>Journal of Virology</i> , 75(14): 6482-6491, 2001.	
	C121	MALTESE et al., "Sequence context of antisense RelA/NF-kappa B phosphorothioates determines specificity", <i>Nucleic Acids Research</i> , 23: 1146-51, 1995.	
	C122	MANZEL et al., "CpG-oligodeoxynucleotide-resistant variant of WEHI 231 cells", <i>Journal of Leukocyte Biology</i> , 66: 817, 1999.	
	C123	MARKIEWICZ et al., "Epitope spreading upon P815 tumor rejection triggered by vaccination with the single class I MHC-restricted peptide P1A", <i>International Immunology</i> , 13(5): 625-32, 2001.	
	C124	MATSON et al., "Nonspecific suppression of [3H]thymidine incorporation by "control" oligonucleotides", <i>Antisense Research and Development</i> , 2(4): 325-30, 1992.	
	C125	MATSUKURA et al., "Regulation of viral expression of human immunodeficiency virus in vitro by an antisense phosphorothioate oligodeoxynucleotide against rev (art/hrs) in chronically infected cells", <i>Proceedings of the National Academy of Science USA</i> , 86: 4244-48, 1989.	
	C126	MCCLUSKIE et al., "CpG DNA is a potent enhancer of systemic and mucosal immune responses against hepatitis B surface antigen with intranasal administration to mice", <i>Journal of Immunology</i> , 161: 4463-6, 1998.	
	C127	MCCLUSKIE et al., <i>Vaccine</i> , 18: 231-237, 2000.	
	C128	MCCLUSKIE et al., "Oral, intrarectal and intranasal immunizations using CpG and non-CpG oligodeoxynucleotides as adjuvants", <i>Vaccine</i> , 19: 413-422, 2001.	
	C129	MCCLUSKIE et al., "CpG DNA is an effective oral adjuvant to protein antigens in mice", <i>Vaccine</i> , 19: 950, 2001.	
	C130	MCCLUSKIE et al., "The potential of oligodeoxynucleotides as mucosal and parenteral adjuvants", <i>Vaccine</i> , 19: 2657-2660, 2001.	
	C131	MCCLUSKIE et al., "The use of CpG DNA as a mucosal vaccine adjuvant", <i>Current Opinions Investigational Drugs</i> , 2(1): 35-9, 2001.	
NMM	C132	MCCLUSKIE et al., "Mucosal immunization of mice using CpG DNA and/or mutants of the heat-labile enterotoxin of Escherichia coli as adjuvants", <i>Vaccine</i> , 19(27): 3759-68, 2001.	

FORM PTO-1449/A and B (Modified) INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICATION NO.: 10/735,592		ATTY. DOCKET NO.: C1037.70038US01	
				FILING DATE: December 11, 2003		CONFIRMATION NO.: 2533	
				APPLICANT: Krieg et al.			
				GROUP ART UNIT: 1645 1645		EXAMINER: MINNIFIELD MINNIFIELD	
Sheet	10	of	12				

NMM	C133	MCCLUSKIE et al., "The potential of CpG oligodeoxynucleotides as mucosal adjuvants", <i>Critical Reviews in Immunology</i> , 21(1-3): 103-20, 2001.		
	C134	MCCLUSKIE et al., "Parenteral and mucosal prime-boost immunization strategies in mice with hepatitis B surface antigen and CpG DNA", <i>FEMS Immunology Medicine Microbiology</i> , 32(3): 179-85, 2002.		
	C135	MCCLUSKIE et al., "Mucosal immunization with DNA vaccines", <i>Microbes and Infection</i> , 1(9): 685-98, 1999.		
	C136	MCCLUSKIE et al., "Intranasal immunization of mice with CpG DNA induces strong systemic and mucosal responses that are influenced by other mucosal adjuvants and antigen distribution", <i>Molecular Medicine</i> , 6(10): 867-77, 2000.		
	C137	MCCLUSKIE et al., "The role of CpG in DNA vaccines", <i>Springer Seminars in Immunopathology</i> , 22(1-2): 125-32, 2000.		
	C138	MCINTYRE et al., "A sense phosphorothioate oligonucleotide directed to the initiation codon of transcription factor NF-kappa B p65 causes sequence-specific immune stimulation", <i>Antisense Research and Development</i> , 3(4): 309-22, 1993.		
	C139	MESSINA et al., "Stimulation of in vitro murine lymphocyte proliferation by bacterial DNA", <i>Journal of Immunology</i> , 147(6): 1759-1764, 1991.		
	C140	MICHELSON et al. "Poly(A).poly(U) as adjuvant in cancer treatment distribution and pharmacokinetics in rabbits", <i>Proceedings of Society of Experimental Biological Medicine</i> , 179: 180, 1985.		
	C141	MOLDOVEANU et al., "CpG DNA, a novel immune enhancer for systemic and mucosal immunization with influenza virus", <i>Vaccine</i> , 16(11-12): 1216-1224, 1998.		
	C142	NEW ENGLAND BIOLABS, 1988-1989 Catalog.		
	C143	NYCE et al., "DNA antisense therapy for asthma in an animal model", <i>Nature</i> , 385: 721-725, 1997.		
	C144	OKADA et al., "Bone marrow-derived dendritic cells pulsed with a tumor-specific peptide elicit effective anti-tumor immunity against intracranial neoplasms", <i>International Journal of Cancer</i> , 78(2): 196-201, 1998.		
	C145	PAL et al., "Immunization with the Chlamydia trachomatis mouse pneumonitis major outer membrane protein by use of CpG oligodeoxynucleotides as an adjuvant induces a protective immune response against an intranasal chlamydial challenge", <i>Infection and Immunity</i> , 70(9): 4812-7, 2002.		
	C146	PARK et al. "Adjuvant effect of polyadenylic.polyuridylic acid on antibody production of recombinant hepatitis B surface antigen in mice", <i>International Journal of Immunopharmacology</i> , 17(6): 513, 1995.		
	C147	PAYETTE et al., "History of vaccines and positioning of current trends", <i>Current Drugs Targets for Infection and Disorders</i> , 1(3): 241-7, 2001.		
	C148	PISETSKY et al., "The immunologic properties of DNA", <i>Journal of Immunology</i> , 156(2): 421-3, 1996.		
	C149	PISETSKY et al., "Stimulation of murine lymphocyte proliferation by a phosphorothioate oligonucleotide with antisense activity for herpes simplex virus", <i>Life Sciences</i> , 54(2): 101-107, 1994.		
	C150	PISETSKY et al., "Immunologic consequences of nucleic acid therapy", <i>Antisense Research and Development</i> , 5(3): 219-225, 1995.		
	C151	PISETSKY et al., "Stimulation of in vitro proliferation of murine lymphocytes by synthetic oligodeoxynucleotides", <i>Molecular Biology Reports</i> , 18: 217-221, 1993.		
	C152	PISETSKY et al., "The influence of base sequence on the immunostimulatory properties of DNA", <i>Immunity Research</i> , 19: 35-46, 1999.		
	C153	RANIERI et al., "Dendritic cell/peptide cancer vaccines: clinical responsiveness and epitope spreading", <i>Immunology Investigations</i> , 29(2): 121-5, 2000.		
	C154	RAZ et al., "Preferential induction of a Th1 immune response and inhibition of specific IgE antibody formation by plasmid DNA immunization", <i>Proceedings of the National Academy of Science USA</i> , 93(10): 5141-5, 1996.		
	C155	ROMAN et al., "Immunostimulatory DNA sequences function as T helper-1-promoting adjuvants", <i>Nature Medicine</i> , 3(8): 849-54, 1997.		
	C156	SAJIC et al., "Parameters of CpG oligodeoxynucleotide-induced protection against intravaginal HSV-2 challenge", <i>Journal of Medical Virology</i> , 71(4): 561-568, 2003.		
	C157	SARMIENTO et al., "In vivo toxicological effects of rel A antisense phosphorothioates in CD-1 mice", <i>Antisense Research and Development</i> , 4: 99-107, 1994.		
	C158	SATO et al., "Immunostimulatory DNA sequences necessary for effective intradermal gene immunization", <i>Science</i> , 273: 352-354, 1996.		
NMM	C159	SCHWARTZ et al., "CpG motifs in bacterial DNA cause inflammation in the lower respiratory tract", <i>Journal of Clinical Investigation</i> , 100(1): 68-73, 1997.		

FORM PTO-1449/A and B (Modified)				APPLICATION NO.: 10/735,592	ATTY. DOCKET NO.: C1037.70038US01
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				FILING DATE: December 11, 2003	CONFIRMATION NO.: 2533
				APPLICANT: Krieg et al.	
				GROUP ART UNIT: 1645 1645	EXAMINER: MINNIFIELD MINNIFIELD
Sheet	11	of	12		

NMM	C160	SETHI et al., "Postexposure prophylaxis against prion disease with a stimulator of innate immunity", <i>Lancet</i> , 360: 229-230, 2002.		
	C161	SPARWASSER et al., "Bacterial DNA and immunostimulatory CpG oligonucleotides trigger maturation and activation of murine dendritic cells", <i>European Journal of Immunology</i> , 28(6): 2045-54, 1998.		
	C162	SPARWASSER et al., "Macrophages sense pathogens via DNA motifs: induction of tumor necrosis factor-alpha-mediated shock", <i>European Journal of Immunology</i> , 27(7): 1671-9, 1997.		
	C163	STACEY et al., "Immunostimulatory DNA as an adjuvant in vaccination against <i>Leishmania major</i> ", <i>Infection and Immunity</i> , 67: 3719-3726, 1999.		
	C164	SUN et al. <i>Journal of Experimental Medicine</i> , 188: 2335, 1998.		
	C165	SUN et al. <i>Springer Seminars in Immunopathology</i> , 22: 77, 2000.		
	C166	TALMADGE et al., "Immunomodulatory effects in mice of polyinosinic-polycytidylic acid complexed with poly-L-lysine and carboxymethylcellulose", <i>Cancer Research</i> , 45(3): 1058-65, 1985.		
	C167	THREADGILL et al., "Mitogenic synthetic polynucleotides suppress the antibody response to a bacterial polysaccharide", <i>Vaccine</i> , 16(1): 76-82, 1998.		
	C168	TOKUNAGA et al., "A synthetic single-stranded DNA, poly(dG,dC), induces interferon-alpha/beta and -gamma, augments natural killer activity, and suppresses tumor growth", <i>Japan Journal of Cancer Research</i> , 79(6): 682-6, 1988.		
	C169	TOKUNAGA et al., "Synthetic oligonucleotides with particular base sequences from the cDNA encoding proteins of <i>Mycobacterium bovis</i> BCG induce interferons and activate natural killer cells", <i>Microbiological Immunology</i> , 36(1): 55-66, 1992.		
	C170	VANDERLUGT et al., "Epitope spreading in immune-mediated diseases: implications for immunotherapy", <i>Nature Reviews in Immunology</i> , 2(2): 85-95, 2002.		
	C171	WAAG et al., "Injection of inactivated phase I <i>Coxiella burnetii</i> increases non-specific resistance to infection and stimulates lymphokine production in mice", <i>Annual New York Academy of Science</i> , 590: 203-214, 1990.		
	C172	WALKER et al., <i>Proceedings of the National Academy of Science, USA</i> , 96: 6970-6975, 1999.		
	C173	WARREN et al., "APC stimulated by CpG oligodeoxynucleotide enhance activation of MHC class I-restricted T cells", <i>Journal of Immunology</i> , 165: 6244, 2000.		
	C174	WEERATNA et al., "Reduction of antigen expression from DNA vaccines by coadministered oligodeoxynucleotides", <i>Antisense & Nucleic Drug Development</i> , 8: 351-356, 1998.		
	C175	WEERATNA et al., "CPG ODN allows lower dose of antigen against hepatitis B surface antigen in BALB/c mice", <i>Immunology Cell Biology</i> , 81(1): 59-62, 2003.		
	C176	WEERATNA et al., "CpG ODN can re-direct the Th bias of established Th2 immune responses in adult and young mice", <i>FEMS Immunology Medicine Microbiology</i> , 32(1): 65-71, 2001.		
	C177	WEERATNA et al., "CpG DNA induces stronger immune responses with less toxicity than other adjuvants", <i>Vaccine</i> , 18(17): 1755-62, 2000.		
	C178	WEERATNA et al., "Priming of immune responses to hepatitis B surface antigen in young mice immunized in the presence of maternally derived antibodies", <i>FEMS Immunology Medicine Microbiology</i> , 30(3): 241-7, 2001.		
	C179	WEINER et al., "Immunostimulatory oligodeoxynucleotides containing the CpG motif are effective as immune adjuvants in tumor antigen immunization", <i>Proceedings of the National Academy of Science USA</i> , 94(20): 10833-7, 1997.		
	C180	WERNETTE et al., "CpG oligodeoxynucleotides stimulate canine and feline immune cell proliferation", <i>Veterinary Immunology and Immunopathology</i> , 84(3-4): 223-236, 2002.		
	C181	WOOLDRIDGE et al. <i>Proceedings of American Association for Cancer Research</i> , 37: 477, 1996.		
	C182	WOOLDRIDGE et al., "Immunostimulatory oligodeoxynucleotides containing CpG motifs enhance the efficacy of monoclonal antibody therapy of lymphoma", <i>Blood</i> , 89(8): 2994-2998, 1997.		
	C183	WU et al., "Receptor-mediated gene delivery and expression in vivo", <i>Journal of Biological Chemistry</i> , 263: 14621-14624, 1988.		
	C184	WYATT et al. "Combinatorially selected guanosine-quartet structure is a potent inhibitor of human immunodeficiency virus envelope-mediated cell fusion", <i>Proceedings of the National Academy of Science USA</i> , 91: 1356-60, 1994.		
NMM	C185	YAMAMOTO et al., "Lipofection of synthetic oligodeoxyribonucleotide having a palindromic sequence of AACGTT to murine splenocytes enhances interferon production and natural killer activity", <i>Microbiological Immunology</i> , 38(10): 831-836, 1994.		

FORM PTO-1449/A and B (Modified) INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICATION NO.: 10/735,592		ATTY. DOCKET NO.: C1037.70038US01	
				FILING DATE: December 11, 2003		CONFIRMATION NO.: 2533	
				APPLICANT: Krieg et al.			
				GROUP ART UNIT: 1645 1645		EXAMINER: MINNIFIELD MINNIFIELD	
Sheet	12	of	12				

NMM ↓ NMM	C186	YAMAMOTO et al., "Unique palindromic sequences in synthetic oligonucleotides are required to induce IFN [correction of INF] and augment IFN-mediated [correction of INF] natural killer activity", <i>Journal of Immunology</i> , 148(12): 4072-4076, 1992.		
	C187	YAMAMOTO et al., "[Commemorative lecture of receiving Imamura Memorial Prize. II. Mode of action of oligonucleotide fraction extracted from Mycobacterium bovis BCG]", <i>Kekkaku</i> , 69(9): 571-4, 1994.		
	C188	YAMAMOTO et al., "Ability of oligonucleotides with certain palindromes to induce interferon production and augment natural killer cell activity is associated with their base length", <i>Antisense Research and Development</i> , 4(2): 119-123, 1994.		
	C189	YAMAMOTO et al., "Synthetic oligonucleotides with certain palindromes stimulate interferon production of human peripheral blood lymphocytes in vitro", <i>Japan Journal of Cancer Research</i> , 85: 775-779, 1994.		
	C190	YI et al., "Rapid induction of mitogen-activated protein kinases by immune stimulatory CpG DNA", <i>Journal of Immunology</i> , 161: 4493, 1998.		
	C191	YI et al., "Rapid immune activation by CpG motifs in bacterial DNA. Systemic induction of IL-6 transcription through an antioxidant-sensitive pathway", <i>Journal of Immunology</i> , 157: 5394-5402, 1996.		
	C192	YI et al., "IFN-gamma promotes IL-6 and IgM secretion in response to CpG motifs in bacterial DNA and oligodeoxynucleotides", <i>Journal of Immunology</i> , 156(2): 558-64, 1996.		
	C193	YI et al., "CpG oligodeoxyribonucleotides rescue mature spleen B cells from spontaneous apoptosis and promote cell cycle entry", <i>Journal of Immunology</i> , 160: 5898, 1998.		
	C194	ZIMMERMANN et al., "CpG oligodeoxynucleotides trigger protective and curative Th1 responses in lethal murine leishmaniasis", <i>Journal of Immunology</i> , 160(8): 3627-3630 1998.		

EXAMINER	/N. M. Minnifield/ (10/20/2006)	DATE CONSIDERED	10/20/2006
----------	---------------------------------	-----------------	------------

#EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

*a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. __, filed __, and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).

**a copy of this patent or patent application is not enclosed pursuant to the waiver by the USPTO of the requirement under 37 C.F.R. 1.98 (a)(2(i)) for patent applications filed after June 30, 2003.

[NOTE - Must provide a copy of any patent, publication, other information listed, even if it was previously submitted to, or cited by, the U.S. Patent Office in an earlier application, unless the earlier application is identified by the IDS and is relied upon for an earlier filing date under 35 U.S.C. §120, and the copy was provided in the earlier application.]